

ZFN



<b>AMENDMENT TRANSMITTAL LETTER</b>				Docket No. 4533-0108PUS1	
Application No. 10/822,761-Conf. #004958	Filing Date April 13, 2004	Examiner S. McGarry	Art Unit 1635		
Applicant(s): Zhigang ZHANG et al.					
Invention: OLIGONUCLEOTIDES ANTAGONIST FOR HUMAN TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA)					
<b>MS Amendment</b> <b>Commissioner for Patents</b> <b>P.O. Box 1450</b> <b>Alexandria, VA 22313-1450</b>					
Transmitted herewith is an amendment in the above-identified application.					
The fee has been calculated and is transmitted as shown below.					
<b>CLAIMS AS AMENDED</b>					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
<b>Total Claims</b>	14	- 20 =	0	x 50.00	0.00
<b>Independent Claims</b>	2	- 3 =	0	x 200.00	0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					
Other fee (please specify):					
<b>TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:</b>					<b>0.00</b>
<input checked="" type="checkbox"/> Large Entity <span style="margin-left: 200px;"><input type="checkbox"/> Small Entity</span>					
<input checked="" type="checkbox"/> No additional fee is required for this amendment.					
<input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of \$ _____. A duplicate copy of this sheet is enclosed.					
<input type="checkbox"/> A check in the amount of \$ _____ is enclosed.					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
<input checked="" type="checkbox"/> The Director is hereby authorized to charge and credit Deposit Account No. <u>02-2448</u> as described below. A duplicate copy of this sheet is enclosed.					
<input checked="" type="checkbox"/> Credit any overpayment.					
<input checked="" type="checkbox"/> Charge any additional filing or application processing fees required under 37 CFR 1.16 and 1.17.					
<i>Robert E. Gagner #42593</i> James M. Slattery Attorney Reg. No.: 28,380				Dated: <u>December 18, 2006</u>	
BIRCH, STEWART, KOLASCH & BIRCH, LLP 8110 Gatehouse Road Suite 100 East P.O. Box 747 Falls Church, Virginia 22040-0747 (703) 205-8000					



Docket No.: 4533-0108PUS1  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Patent Application of:  
Zhiqing ZHANG et al.

Application No.: 10/822,761

Confirmation No.: 004958

Filed: April 13, 2004

Art Unit: 1635

For: OLIGONUCLEOTIDES ANTAGONIST FOR  
HUMAN TUMOR NECROSIS FACTOR  $\alpha$   
(TNF-  $\alpha$ )

---

Examiner: S. McGarry

**AMENDMENT IN RESPONSE TO NON-FINAL OFFICE ACTION**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INTRODUCTORY COMMENTS**

In response to the Office Action dated September 18, 2006, please amend the above-identified U.S. patent application as follows:

**Amendments to the Specification** begin on page 2 of this paper.

**Amendments to the Claims** are reflected in the listing of claims that begins on page 4 of this paper.

**Remarks** begin on page 9 of this paper.